Tufts’ Cardio-Oncology Research Group: Investigating the Impacts of Successful Cancer Drugs on Surviving Patients’ Cardiovascular Condition

Tufts’ Cardio-Oncology Research Group Investigating the Impacts of Successful Cancer Drugs on Surviving Patients’ Cardiovascular Condition TrialsiteN

The Tufts’ Cardio-Oncology Research Group, formed three years ago by Iris Jaffe, cardiologist and executive director of the Molecular Cardiology Research Institute (MCRI) at Tufts Medical Center, represents a response to a growing recognition that the tremendous breakthroughs in cancer therapies over the last decade have led to an unintended consequence: a growing number of cancer patients that survive their primary illness but face a range of cardiovascular side effects. With 16 million or so human cancer survivors in the U.S. alone, many face heart and blood-vessel side effects, unanticipated when the life saving cancer drugs were approved. The Cardio-Oncology Research Group collaborates with veterinarians to improve understanding of how to assess and treat the cardiovascular effects of the growing list of life-saving cancer therapies. This collaborative group works on both people at Tufts Medical Center and pets at Cummings School of Veterinary Medicine.

Recently Genevieve Rajewski writing for Tufts Now reported on this important topic; a medical quandary that has led to the creation of a nascent field of medicine known as cardio-oncology, focused on how to help treat cancer survivors whose life-saving cancer therapies actually led to heart and blood-vessel challenges.

Lead Research/Investigator

Iris Jaffe, MD, PhD, cardiologist and Executive Director of the Molecular Cardiology Research Institute (MCRI)